Status:
TERMINATED
WithDRawal Impact Of Postoperative Beta-Blocker
Lead Sponsor:
Yale University
Collaborating Sponsors:
Glenn Memorial Fund
Conditions:
Coronary Artery Bypass
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators will evaluate the impact of withdrawing beta-blocker medication after coronary artery bypass surgery with this randomized controlled trial.
Detailed Description
Aim 1: The primary aim is to evaluate the impact of withdrawing BB on exercise capacity (peak oxygen consumption, VO2 max) in patients who underwent CABG. The investigators hypothesize that withdrawin...
Eligibility Criteria
Inclusion
- Participants who underwent coronary artery bypass graft(CABG) surgery at Yale New Haven Hospital who presented to 1-month postoperative visit
- ejection fraction \>50%, and in sinus rhythm at the time of hospital discharge or enrollment.
Exclusion
- those who underwent combined valve + CABG surgery or aorta + CABG surgery.
Key Trial Info
Start Date :
November 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2024
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT05414331
Start Date
November 4 2022
End Date
May 30 2024
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale New Haven Hospital
New Haven, Connecticut, United States, 06511